Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Ventyx Biosciences, Inc. VTYX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
51/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$33.86
+141.9%

Ventyx Biosciences, Inc. (VTYX) is a Biotechnology company in the Healthcare sector, currently trading at $14.00. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is VTYX = $34 (+141.9% upside).

Net income is $135M (loss), growing at -28.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $11M against $254M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 17.97 (strong liquidity). Debt-to-assets is 3.9%. Total assets: $277M.

Analyst outlook: 4 / 13 analysts rate VTYX as buy (31%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$33.86
▲ 141.86% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Ventyx Biosciences, Inc., the average price target is $33.86, with a high forecast of $60.00, and a low forecast of $6.00.
Highest Price Target
$60.00
Average Price Target
$33.86
Lowest Price Target
$6.00

VTYX SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VTYX

✓
VALUE Pass
100/100
VTYX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $34, implying +142.9% from the current price $14. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
VTYX: +0%/yr revenue is, -28.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet VTYX: Debt-to-Equity (D/E) ratio 0.04 (conservative), Current ratio is 17.97 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
VTYX: Gross margin is 0% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 4 / 13 analysts rate VTYX as buy (31%). Analyst consensus target is $34 (+142.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.783-25
Volume5.4M
Avg Volume (30D)3.81M
Market Cap$1B
Beta (1Y)1.27
Share Statistics
EPS (TTM)-1.97
Shares Outstanding$68.48M
IPO Date2021-10-21
Employees81
CEOSheila K. Gujrathi
Financial Highlights & Ratios
EBITDA$-133.77M
Net Income$-135.12M
Operating Income$-148.45M
Total Cash$217.32M
Total Debt$10.79M
Net Debt$-16.47M
Total Assets$276.56M
Price / Earnings (P/E)-7.1
Analyst Forecast
1Y Price Target$45.00
Target High$60.00
Target Low$6.00
Upside+221.4%
Rating ConsensusHold
Analysts Covering13
Buy 31% Hold 69% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS92332V1070

Price Chart

Track all markets on TradingView
VTYX
Ventyx Biosciences, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.78 52WK RANGE 25.00

People Also View

VRNA
VRNA
Verona Pharma plc
$106.91
+0.11%
 UTHR
UTHR
United Therapeutics Corporation
$578.54
+0.16%
 ASND
ASND
Ascendis Pharma A/S
$249.84
+0.52%
 PCVX
PCVX
Vaxcyte, Inc.
$62.76
+1.64%
 CERE
CERE
Cerevel Therapeutics Holdings, Inc.
$44.96
+0.74%
 NUVL
NUVL
Nuvalent, Inc.
$105.02
+1.28%
 ACLX
ACLX
Arcellx, Inc.
$114.89
+0.02%
 PTGX
PTGX
Protagonist Therapeutics, Inc.
$104.72
+7.33%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message